The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific

Melanoma Research

Volumn 16, Issue 6, 2006, Pages 527-535

  Kissel, Christine K ^a   Schadendorf, Dirk ^a   Röckmann, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Caspases; Drug resistance; Melanoma; Mitochondria

Indexed keywords

CASPASE; CASPASE 9; CISPLATIN; CYTOCHROME C; ETOPOSIDE; GYRASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 33845567214     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3280103a7c     Document Type: Article

References (36)

1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
2. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001; 93:617-622.
3. Hersey P. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol 2006; 18:189-196.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108:153-164.
5. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-49.
6. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157:1415-1430.
7. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776.
8. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407:789-795.
9. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
10. Reed JC. Cytochrome c: can't live with it-can't live without it. Cell 1997; 91:559-562.
11. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
12. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-489.
13. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1:949-957.
14. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1998; 1366:127-137.
15. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305:626-629.
16. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001; 2:63-67.
17. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. Faseb J 1999; 13:2061-2070.
18. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276:3238-3246.
19. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-211.
20. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res 1997; 17:4359-4370.
21. Rockmann H, Schadendorf D. Role of apaf-1 in melanoma drug resistance and apoptosis. J Invest Dermatol 2005; 125:386-387.
22. Sinha P, Poland J, Kohl S, Schnolzer M, Helmbach H, Hutter G, et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 2003; 24:2386-2404.
23. Wittig R, Nessling M,Will RD, Mollenhauer J, Salowsky R, Munstermann E, et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002; 62:6698-6705.
24. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121:172-176.
25. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000; 82:488-491.
26. Lage H, Helmbach H, Grottke C, Dietel M, Schadendorf D. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett 2001; 494:54-59.
27. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002; 118:923-932.
28. Sanchez-Alcazar JA, Khodjakov A, Schneider E. Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res 2001; 61:1038-1044.
29. Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem 2000; 275:32438-32443.
30. Park SY, Cho SJ, Kwon HC, Lee KR, Rhee DK, Pyo S. Caspase-independent cell death by allicin in human epithelial carcinoma cells: involvement of PKA. Cancer Lett 2005; 224:123-132.
31. Koh DW, Dawson TM, Dawson VL. Poly(ADP-ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci 2005; 62:760-768.
32. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000; 97:14376-14381.
33. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62:924-931.
34. Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 2000; 88:535-546.
35. Nessling M, Kern MA, Schadendorf D, Lichter P. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. Cytogenet Cell Genet 1999; 87:286-290.
36. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001; 92:123-129.